Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Overview of attention for article published in Journal of Clinical Oncology, June 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 7 news outlets
policy: 1 policy source
twitter: 89 X users

patent: 3 patents
f1000: 1 research highlight platform
guideline: 6 clinical guideline sources

Readers on

mendeley: 386 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Niraparib (Zejula) for first line Ovarian Cancer - Details - Niraparib (Zejula) first line OC – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 21 Sep 2020

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.